Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
- 3 September 2021
- journal article
- editorial
- Published by Elsevier BV in The Lancet Haematology
- Vol. 8 (10), e681-e683
- https://doi.org/10.1016/s2352-3026(21)00274-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesAnnals of Internal Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsThe New England Journal of Medicine, 2021
- Antibody response after second BNT162b2 dose in allogeneic HSCT recipientsThe Lancet, 2021
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort studyThe Lancet Haematology, 2021
- COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyLeukemia, 2021
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2Nature Medicine, 2021
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studyThe Lancet Haematology, 2021
- Antipneumococcal Seroprotection Years After Vaccination in Allogeneic Hematopoietic Cell Transplant RecipientsClinical Infectious Diseases, 2019